摘要
目的探析帕金森病伴抑郁症(PDD)患者临床应用帕罗西汀治疗的有效性及不良反应评价。方法该研究选取2018年1月—2020年10月该院96例PDD患者临床资料,根据随机数表法进行分组,即对照组与观察组,各48例。对照组施行常规治疗,与观察组加用帕罗西汀治疗的临床效果进行对比。结果在临床疗效评价中,观察组明显高于对照组,数据为95.83%、79.17%,对比差异有统计学意义(χ^(2)=6.095,P=0.014);从抑郁情况改善方面,治疗前,观察组的SDS评分、HAMD评分、MMSE评分(76.55±5.73)分、(39.76±3.28)分、(15.75±2.89)分较对照组(76.94±5.34)分、(39.89±3.68)分、(15.61±2.95)分各项指标评分对比差异无统计学意义(t=0.345、0.183、0.235,P=0.731、0.855、0.815);治疗后,观察组的SDS评分、HAMD评分(50.05±3.03)分、(12.18±1.21)分明显低于对照组(62.67±4.19)分、(22.75±2.38)分,差异有统计学意义(t=16.909,27.428,P<0.001);MMSE评分(22.54±1.13)分明显高于对照组(18.68±1.55)分,差异有统计学意义(t=13.942,P<0.001)。在相关血清指标改善方面,治疗前,观察组的Hcy水平、血尿酸水平(19.23±2.34)、(226.54±20.79)mmol/L,对照组为(19.25±2.42)、(226.81±20.28)mmol/L,差异无统计学意义(t=0.041、0.064,P=0.967、0.949);治疗后,观察组Hcy水平(9.75±1.05)mmol/L明显低于对照组(16.25±1.63)mmol/L,血尿酸水平(302.82±29.38)mmol/L显著高于对照组(254.82±20.95)mmol/L,对比差异有统计学意义(t=23.226、9.216,P<0.001)。在不良反应率评价中,观察组明显低于对照组,数据为4.17%、25.00%,对比差异有统计学意义(χ^(2)=8.362,P=0.004)。结论针对临床罹患帕金森病伴抑郁患者进行帕罗西汀治疗的疗效显著,可显著改善其抑郁症状,降低不良反应率,值得临床借鉴推广。
Objective To analyze the effectiveness and adverse reaction evaluation of clinical application of paroxetine in patients with Parkinson's disease with depression(PDD).Methods The study selected the clinical data of 96 patients with PDD in the hospital from January 2018 to October 2020.Groups were grouped according to the random number table method,namely the control group and the observation group,each with 48 cases.The control group received conventional treatment,and the clinical effect of paroxetine treatment was compared with the observation group.Results In the clinical efficacy evaluation,the observation group was significantly higher than the control group,the data were 95.83%,79.17%,and the difference was a statistically significant(χ^(2)=6.095,P=0.014);from the aspect of improvement in depression,before treatment,the observation group SDS score,HAMD score,MMSE score(76.55±5.73)points,(39.76±3.28)points,(15.75±2.89)points,compared with the control group(76.94±5.34)points,(39.89±3.68)points,(15.61±2.95)points,there was no statistically significant difference in the scores of each index(t=0.345,0.183,0.235,P=0.731,0.855,0.815);after treatment,the observation group's SDS score,HAMD score(50.05±3.03)points,(12.18±1.21)points was significantly lower than that of the control group(62.67±4.19)points and(22.75±2.38)points,the difference was statistically different(t=16.909,27.428;P<0.001);the MMSE score(22.54±1.13)points was significantly higher compared with the control group(18.68±1.55)points,there was the difference was statistically significant(t=13.942,P<0.001).Regarding the improvement of related serum indicators,before treatment,the Hcy level,blood uric acid level(19.23±2.34)mmol/L,(226.54±20.79)mmol/L,the control group was(19.25±2.42)mmol/L,(226.81±20.28)mmol/L,the difference was statistically significant(t=0.041,0.064,P=0.967,0.949);after treatment,the Hcy level of the observation group(9.75±1.05)mmol/L was significantly lower than that of the control group(16.25±1.63)mmol/L,the blood
作者
臧晓文
ZANG Xiaowen(Department of Neurology,Liaocheng Veterans Hospital,Liaocheng,Shandong Province,252000 China)
出处
《系统医学》
2021年第14期16-19,24,共5页
Systems Medicine
基金
科学技术成果评价(202004045s)山东顺城(评价)字[2020]第45号。
关键词
帕罗西汀
帕金森病
抑郁症
临床疗效
不良反应
Paroxetine
Parkinson's disease
Depression
Clinical efficacy
Adverse reactions
